Biomarkers for disease burden of neuroblastoma

The present invention relates to monitoring disease and therapy response. More in particular, the present invention discloses serum/plasma miRNA markers for assessment of disease burden in human neuroblastoma. Indeed, the present invention discloses that the more the tumor is spread throughout the body, the higher the levels of particular miRNAs in serum/plasma are. Consequently, the latter markers can be used in methods and kits for assessing the neuroblastoma disease burden.

Octrooi-publicatienummer: EP3724356

Jaar aanvraag: 2018

Jaar toekenning: 2024

Jaar van publicatie: 2024

Status: Aangevraagd

Technologiedomeinen: Biotechnologie

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie Universiteit Gent